Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT07511751
Recruiting Not applicable

COMPARISON OF THREE TREATMENT MODALITIES IN MYOFASCIAL PAIN SYNDROME

NCT07511751 · tracked via the Priya Life Science Turkey tracker
Sponsor
ALİEMAN
Phase
Not applicable
Started
2026-03-10
Last updated
2026-05-07

Condition(s) studied

Myofascial Pain Syndrome

Investigational drug(s) / intervention(s)

Dry NeedlingExtracorporeal Shock Wave TherapyPulsed radiofrequency(PRF)

Dry Needling: Dry needling applied to myofascial trigger points

Extracorporeal Shock Wave Therapy: Extracorporeal shock wave therapy applied to the painful area

Pulsed radiofrequency(PRF): Pulsed radiofrequency applied to the target area for the treatment of myofascial pain syndrome

Study summary

This study aims to compare the effectiveness of dry needling, extracorporeal shock wave therapy (ESWT), and pulsed radiofrequency (PRF) in patients with chronic musculoskeletal pain. The primary outcomes include pain intensity and functional status. Patients will be randomly assigned to different treatment groups, and outcomes will be evaluated before and after the interventions. The results of this study are expected to contribute to determining the most effective treatment method for pain management.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Age between 18 and 65 years * Clinically diagnosed myofascial pain syndrome * Back pain lasting at least 3 months * Failure to respond to conservative treatments Exclusion Criteria: * History of cervical surgery or cervical disc pathology * Fibromyalgia * Shoulder pathologies * Coagulation disorders or use of anticoagulant therapy * Infection, malignancy, or inflammatory spinal diseases

Primary outcome measure(s)

  • Pain Intensity — Baseline, 1 month, and 3 months after treatment
    Pain intensity will be assessed using the Numeric Rating Scale(NRS). Pain intensity will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain severity.

Trial sites (1)

FacilityCityRegionStatus
Sakarya Training and Research Hospital Adapazarı Sakarya Recruiting

Other trials for the same condition

ACUTE EFFECT OF DIAPHRAGMATIC BREATHING ON POSTOPERATIVE UPPER TRAPEZIUS PAIN Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07511751 on ClinicalTrials.gov ↗ ← All trials in Turkey